Trade REPL anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Replimune Group, Inc. (REPL) is trading at US$15.04, down 1.64% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$1.39B. Over the past 52 weeks, REPL has traded between US$1.50 and US$16.33. On Syfe you can trade REPL with $0 commission and add it to your watchlist.
| Previous close | US$15.29 |
|---|---|
| Market cap | US$1.39B |
| 52-week range | US$1.50 – US$16.33 |
| Volume | 905.98K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Year: 2018
Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12
Aug 7, 11:15 AM · MT Newswires
Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11
Aug 4, 11:44 AM · MT Newswires
Replimune Group, Inc. (REPL) stock is trading at US$15.04, -1.64% from the previous close of US$15.29.
The market cap for Replimune Group, Inc. (REPL) stock is approximately US$1.39B.
The 52-week high for Replimune Group, Inc. (REPL) stock is US$16.33.
The 52-week low for Replimune Group, Inc. (REPL) stock is US$1.50.
Replimune Group, Inc. (REPL) does not currently pay a dividend.
Stay on top of REPL
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
